Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Ovid Therapeutics Inc. (OVID) is a Biotechnology company based in US with a market capitalization of $317.8M. Revenue grew 1181.3% year-over-year and free cash flow was negative at -$38.3M. This page tracks OVID's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 23 employees · IPO May 5, 2017
Valuation
Valuation & price
$2.63as of May 17, 2026· -11.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.43
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$317.8M
Market cap
1181.3%
Revenue growth (YoY)
95.9%
Gross margin
-$38.3M
Free cash flow (USD)
-$56.2M
Net debt
Net cash position
4.0%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 8, 2026Filing
Executive Transition
- 8-K eventJun 11, 2026Filing
Annual Meeting Results
- 8-K eventJun 3, 2026Filing
Director Appointment
- 8-K eventMay 12, 2026Filing
Business Updates and Financial Results
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- FinancingApr 21, 2026Filing
Securities Registration
- 8-K eventApr 20, 2026Filing
Warrant Expiration
Questions
Frequently asked questions
What is Ovid Therapeutics Inc.'s market cap?
Ovid Therapeutics Inc. (OVID) has a market capitalization of $317.8M.
What is OVID's P/E ratio?
A meaningful P/E ratio is not available for OVID — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is OVID's price-to-book (P/B) ratio?
OVID trades at 2.43 times book value per share.
Are insiders buying OVID stock?
SEC Form 4 filings show no open-market insider buys at Ovid Therapeutics Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.